Web Design
Publications
  1. Bart T, Waeber B, Wohler D, Schubiger JL, Brunner HR: Langzeitblutdruckmessung in der Praxis. Ergebnisse einer klinischen Erfahrungsstudie mit Cilazapril, D inf Arzt-Gaz Méd 15, 1299-1307 (1992)
     
  2. Martina B, Weinbacher M, Gasser P, Rhyner K, Köhler M, Wohler D, LeBloch Y and Bart T: Efficacy and Tolerability of 5 mg of Cilazapril plus 12.5 mg of Hydrochlorothiazide in Mild-to-Moderate Hypertension: Results of 24-Hour Ambulatory Blood Pressure Monitoring. J Cardiovasc Pharmacol, 24 (Suppl. 3), 89-92 (1994).
     
  3. Weinbacher M, Martina B, Gasser P, Köhler M and Bart T: Nail Fold Capillaroscopy and Echocardiography in Mild-to-Moderate Hypertension treated with Cilazapril plus Hydrochlorothiazide: First Results. J Cardiovasc Pharmacol, 24 (Suppl. 3), 83-85 (1994).
     
  4. Amsler F, Bart T, Baumann M, Becker W, Stump D: Projekt Challenger: Eine prozeßorientierte Außendienst-Analyse. Pharma-Marketing-Journal, 1, 14-18 (1995).
     
  5. Weinbacher M, Martina B, Gasser P, Bart T, Drewe J, Gyr K: Gibt es einen Zusammenhang zwischen Luftdruck und Blutdruck? Therapiew Schweiz, 11, 540 (1995).
     
  6. Weinbacher M, Martina B, Bart T, Drewe J, Gasser P, Gyr K: Blood pressure and atmospheric pressure. In: Time-Dependent Structure And Control Of Arterial Blood Pressure. Annals of the New York Academy of Sciences, 783, 335-336 (1996).
     
  7. Baumann M, Bart T: Die “Swiss Posicor Database” als Epidemiologie- und Marketing-Instrument. “Individuelle Erfahrung und kollektive Verantwortung - Individuelle Verantwortung und kollektive Erfahrung”: Pharma-Marketing-Journal, 2, 48-50 (1998).
     
  8. Martina B, Lorz W, Frach B, Bart T, Battegay E: The effects of Mibefradil and Enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial. J Cardiovasc Pharmacol, 33 (4), 647-651 (1999)
     
  9. Bart T: The ‘e’ in Clinical Research. World Market Research Council, Business Briefing Pharmatech 2002, May 2002
     
  10. Bart T: EDC: quo vadis? A short overview of the current practice and possible future developments in clinical research electronic data capture. European Pharmaceutical Contractor, Autumn 2002, 98 – 101 (2002).
     
  11. Bart T: Clinical Research and Data Privacy: A Comparison of U.S. and European Approaches and Philosophies. European Pharmaceutical Contractor, Spring 2003, 94 – 98 (2003).
     
  12. Bart T: Comparison of EDC to Paper Data Collection: Is there really an advantage? World Market Research Council, Business Briefing Pharmatech 2003, May 2003.
     
  13. Bart T, Jansen KA: Pharma-Kommunikation 2004: Die Rolle von Aussendienst, Internet und Telefon, Pharma Marketing Journal, 1, 20-23 (2004).
     
  14. Bart T, Jansen KA: Pharma-Marketing-Mix, TeleTalk, 3, 46 (2004).
     
  15. Bart T. The drug regulation process in the DRC in comparison with Switzerland - mechanisms, deficiencies, avenues. Master´s Thesis of the Swiss public health Program, October 2006. Abstract available on: www.public-health-edu.ch/new/Abstracts/BT_26.10.06.pdf
     
  16. Bart T: Pharma-Parallelimporte: Hintergrund, Managed Care 7/8, 27-29 (2007)
     
  17. Bart T: Parallel Trade of Pharmaceuticals: A Review of Legal, Economic and Political Aspects. Value in Health, 11, 5, 996 – 1005 (2008) doi: 10.1111/j.1524-4733.2008.00339.x
     
  18. Brand A, Rebulla P, Engelfriet CP, Reesink HW, Beguin Y, Baudoux E, Kögler G, Ebrahimi M, Grazzini G, Nanni Costa A, Bosi A, Sacchi N, Lombardini L, Pupella S, Lecchi L, Calderón Garcidueñas ED, van Beckhoven JM, de Wit HJC, Fibbe WE, Zhiburt EB, Bart T, Beksaç M, Navarrete C & Regan F: Cord blood banking. Vox Sanguinis, 95, 335–348 (2008)
     
  19. Reesink HW, Panzer S, Dettke M, Gabriel C, Lambermont M, Deneys V, Sondag D, Dickmeiss E, Fischer-Nielsen A, Korhonen M, Krusius T, Ali A, Tiberghien P, Schrezenmeier H, Tonn T, Seifried E, Klüter H, Politis C, Stavropoulou-Gioka A, Parara M, Flesland Ø, Nascimento F, Balint B, Marin P, Bart T, Chen FE & Pamphilon DH. New cellular therapies: Is there a role for transfusion services? Vox Sanguinis 97, 77–90 (2009)
     
  20. Veldhuizen I, Follea G, DeGiorgio A, Bart T, Fontana S, Tschaggelar A, Levy G. Donor Recruitment. In: Donor Management Manual, ed. De Kort W, Veldhuizen I. Nijmegen, the Netherlands, DOMAINE, 2010. ISBN 978-90-815585-1-8.
     
  21. Bart T. Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells. ClinicoEconomics and Outcomes Research, 2 , 141–147 (2010)
     
  22. Nicoloso de Faveri G, Schwabe R, Bart T. Swiss Blood Stem Cells: More than Just a Registry. Transfus Med Hemother 38, 300–307 (2011). DOI: 10.1159/000331493
     
  23. Romagnoli S, Bart T, Bürkli P, Halter J. Considérations éthiques et juridiques sur les modalités du don dans la transplantation. Jusletter, 29 August 2011. Editions Weblaw, Bern, Switzerland.
     
  24. Wagner AM, Surbek D, Nicoloso G, Bart T, Schwabe R, Castelli D, Troeger C, Baerlocher GM. Nabelschnurblut-Stammzellspende: Wie ist der heutige Stand? Schweiz Med Forum 11(39), 676–680 (2011)
     
  25. Bart T. Economic Sustainability of Public Cord Blood Banking. Abstract OS 4.02. Transfus Med Hemother; 39
    (suppl 1), 7 (2012)
     
  26. Bart T. Motivation for Blood Stem Cell Donation. Abstract OS 9.03. Transfus Med Hemother; 39 (suppl 1), 15 (2012)
     
  27. Bart T, Boo M, Balabanova S, Fischer Y, Nicoloso G, Foeken L, Oudshoorn M, Passweg J, Tichelli A, Kindler V, Kurtzberg J, Price T, Regan D, Shpall EJ, Schwabe R: Impact of Selection of Cord Blood Units from the United States and Swiss Registries on the Cost of Banking Operations. Transfus Med Hemother; 40:14–20 (2013).
    doi: 10.1159/000345690.
     
  28. Volken T, Weidmann C, Bart T, Fischer Y, Klüter H, Rüesch P: Individual Characteristics Associated with Blood Donation: A Cross-National Comparison of the German and Swiss Population between 1994 and 2010. Transfus Med Hemother; 40(2):133-138 (2013). DOI:10.1159/000349985
     
  29. Bart, T. Cord blood banking in Europe and worldwide: factors of organization and sustainability. ISBT Science Series, 8: 109–110 (2013). doi: 10.1111/voxs.12023
     
  30. Bart T, Volken T, Fischer Y, Mansouri Taleghani B. Giving Blood and Enrolling on the Stem Cell Donor Registry: Ranking of Obstacles and Motives in Switzerland. Transfus Med Hemother; 41(4):264-272 (2014). DOI: 10.1159/000365457
     
  31. Volken T, Buser A, Holbro A, Bart T, Infanti L. Blood donor to inactive donor transition in the Basel region between 1996 and 2011: a retrospective cohort study. Vox Sanguinis 04 (2015); FirstView. DOI:10.1111/vox.12269
     
  32. Spierings E, Wang T, Niemann M, Bart T, Geneugelijk K, Lee SJ, Haagenson M, Spellman S. Analysis of Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) in Mismatched Unrelated Donor Hematopoietic Stem Cell Transplants (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Cohort Study
    Biology of Blood and Marrow Transplantation 23(3):S201 (2017) DOI: 10.1016/j.bbmt.2016.12.341
     
  33. Mueller SM, Gysin S, Schweitzer M, Schwegler S, Haeusermann P, Itin P, Bart T, Spieler Denz R, Steffen T, Kuehl R, Widmer AF and Brandt O: Implementation and evaluation of an algorithm for the management of scabies outbreaks. BMC Infectious Diseases (2019) 19:200 https://doi.org/10.1186/s12879-019-3818-5
     
[Home] [Activity] [Education] [Military Service] [Languages] [Publications] [Rushmore]